Lu Wang, Chief of the Drug Administration and Medical Equipment Section of the Bureau of Animal Husbandry and Veterinary Medicine of the Ministry of Agriculture and Rural Affairs, and his entourage visited Huiliao Bio for inspection and research.

On November 4th, Lu Wang, Director of the Pharmaceutical and Medical Devices Division of the Bureau of Animal Husbandry and Veterinary Medicine under the Ministry of Agriculture and Rural Affairs, along with a delegation, visited Suzhou Huiliao Biotechnology for a research and inspection tour. They were accompanied by relevant leaders from the Provincial Department of Agriculture and Rural Affairs, the Municipal Bureau of Agriculture and Rural Affairs, and the Economic Development Committee of the Industrial Park. The purpose of this visit was to gain insights into the development of the animal biopharmaceutical industry within the industrial park.

During the visit, Director Lu Wang and his delegation toured the cultural exhibition hall and experimental facilities of Suzhou Huiliao, gaining an understanding of the company's achievements and progress, as well as forming an initial impression of Suzhou Huiliao Biotechnology.

At the symposium, Professor Zhao Lixiang, the co-founder, provided a brief overview of the company's profile, key pipeline Strategic, regulatory submission progress, and development strategy. He pointed out that mRNA animal vaccines, being a product not yet officially submitted for approval in China, have presented numerous challenges during the submission process. He expressed hope that government departments at all levels could fully consider the challenges faced by the company and provide more policy support and guidance.

Following this, both sides engaged in in-depth discussions on topics such as R&D investment, product costs, new veterinary drug registration, and future development strategies. Director Lu highly commended Huiliao Biotechnology for its efforts in developing new productive forces in veterinary biologics and fully acknowledged the achievements made by the industrial park in and the of empowerment matters, such as veterinary drug production licenses. He also offered valuable opinions and suggestions on promoting the high-quality development of the animal biopharmaceutical industry within the park.

Through this research and inspection, Huiliao Biotechnology will earnestly implement the guidance provided, continue to enhance the company's capabilities, and make new contributions to the development of the animal biopharmaceutical industry.

#About Suzhou Huiliao #

Suzhou Huiliao Biotechnology is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.